THE EXPERT’S OPINION – Researcher at Inserm, Arnaud Chêne explains that there is “a great inequity in the face of the disease”. Due to production costs and treatment prices which remain very high.
During the last decades, monoclonal antibody therapy has proven to be very effective for the treatment of many diseases such as cancers (in particular B lymphomas), chronic inflammatory diseases (multiple sclerosis, rheumatoid arthritis) as well as certain diseases of the infectious origin such as Covid-19.
But since this type of immunotherapy is based on the use of antibodies that are complicated to create and produce on a large scale, the production costs and treatment prices remain very high. Thus, in rich countries or for wealthy individuals, monoclonal antibodies have become a mainstay of medical care while in poorer countries or for people with limited financial resources, effective monoclonal antibody therapies are simply unaffordable. This results in great inequity in the face of disease. Develop new technologies to reduce the cost of producing antibodies…
This article is for subscribers only. You have 80% left to discover.
Black Friday
-70% on digital subscription
Already subscribed? Login